Macropore biosurgery: Charttechnischer Kauf

Broemme bist du wieder drin?

Oder kriegst du noch tiefere Chance? Wenn man sieht was andere Stammzeller für MKs haben, und noch auf Jahre nichts am Markt....

3,53€ nicht optimal der Nachkauf, aber ziemlich ok im Moment....

 

Einstandspreis 5.12$ Mein weiteres Nachkauflimit bei 4.50$ ist dann doch nicht ganz erreicht worden - bin ich aber nicht böse drüber.

©

Es genügt nicht, keine Gedanken zu haben, man muss auch unfähig sein, sie auszudrücken.  

erinnert.
Dachte du hättest verkauft gehabt. Na Hauptsache da kommt wieder Schwung in die Bude. ;)  

, dass das wohl kein schlechter Zeitpunkt war, ich selber hatte aber nicht verkauft.

©

Es genügt nicht, keine Gedanken zu haben, man muss auch unfähig sein, sie auszudrücken.  

mittlerweile bin ich aber seit EUR 4,56 erneut wieder an Bord.  

Morgen die Zahlen.
Ist aber immer eine Frage des interpretationswillens und des Ausblicks, denn nennenswerte operative Umsätze gibts kaum, wobei MS anfallen und zuschreibungen....  

etwas höher bei 5.29$.

Früher habe ich ja grundsättzlich vor den Zahlen alles rausgeschmissen, aber da ich hier eher mittel- bis langfristig denke, lass ich es mal drauf ankommen :-)

©

Es genügt nicht, keine Gedanken zu haben, man muss auch unfähig sein, sie auszudrücken.  

 

CYTX to Raise $6 Million

Dear Friends and Investors,

Cytori Therapeutics (NASDAQ: CYTX) entered into a strategic equity agreement with Green Hospital Supply, Inc. (TYO: 3360), one of the leading medical equipment suppliers in Japan, who will purchase 1.0 million shares of Cytori common stock at $6.00 per share. The transaction will close on or about April 12, 2007, subject to satisfaction of customary closing conditions.

“With this equity position in Cytori, Green Hospital Supply is making its first strategic investment in the emerging field of regenerative medicine,” said Mr. Kunihisa Furukawa, President of Green Hospital Supply. “We have the required infrastructure and consulting experience to effectively provide and integrate certain regenerative medicine technologies, which may include cell preservation services, to medical centers throughout Japan.”

“This deal bolsters our cash position, adds another strategic financial partner who shares our vision for regenerative medicine, and allows us to maintain our focus on the development of therapeutic applications for the Celution™ System and its near-term launch in Europe,” said Christopher J. Calhoun, chief executive officer of Cytori Therapeutics. “We have jointly identified Future collaborative opportunities, which we look forward to further exploring.”

For more details on Green Hospital, please view attached document.

Regards,

Cytori Therapeutics
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

Toll. Ein Klinikbetreiber steigt bei Cytori ein. Damit klappts noch besser mit klinischer Entwicklung.

 

shit, falsch gelesen.
Krankenhausausrüster! Habe mich von “We have the required infrastructure" täuschen lassen.

Aber auch nicht schlecht einen führenden Lieferanten in Japan zu haben, der in allen Kliniken rumkommt.
 

 

Weiteres muß wohl noch abgewartet werden, oder was meinst Du Ecki.  

dass ich nicht in Panik verfallen bin und bei dem Kurseinbruch meine gerade erst gekauften Papierchen wieder mit Verlust abgestoßen habe. Hoffentlich entwickelt sich cytx jetzt weiter positiv.
Tschau Gretel  

Die Story stimmt m.E. jedenfalls. So etwas hängt auch viel von einer gewissen Lobby U(Geld) und auch gewissen "Mitspielern" (Vermarktung)ab. Nur wenn das mal positiv rübergebracht wird, kann das Papier noch viel Freude bereiten. Dessen bin ich mir ganz sicher.  

Die cashsitutaion ist wesentlich verbessert (natürlich auch verwässert).

Aber nun laufen in verschiedenen Bereichen die Studien, und ab 2008 wird Goldgräberstimmung aufkommen.

Der Wert wird heftig volatil bleiben, aber ich habe hier ein sehr gutes Gefühl, das man mit Cytori noch mehrfach verdoppeln kann.....

Nicht heute oder morgen aber die nächsten Jahre. Das rein-raus ist wieder immer schwierig und anspruchsvoll, aber als Beimischung sollte man ohne bad news auch liegenlassen können.  

 

Chart öffnen

Die 5,21 genommen und gleich bis zur nächsten Hürde hoch.
Die 6 bieten sich jetzt natürlich als Hürde an. Da kommt eh der kurze Downtrend, das ist der Platzierungspreis und ausserdem neigen so Marabuzo-Kerzen wie die aktuelle zur 50% korrektur.

Was auch toll ist: Alle Indikatoren noch weit unten, aber das Volumen zieht gewaltig an. Cytori scheint so langsam an der Nasi anzukommen.

Insofern mein limit-Nachkauftipp:
Bei um die 5,30 USD wäre wohl ein Super-abgriff, wenn er denn nochmal gelingt, z.B. morgen bei ersten Unsicherheiten zu den Zahlen, oder auch nächste Woche mit bröckelndem Umfeld.....

Charttechnisch Sonnenschein aber erst über 7.  

Mal abwarten, wie sich der Kurs in den nächsten Tagen entwickeln wird.  

DGAP-Ad hoc: Cytori Therapeutics, Inc.

14:49 30.03.07

Ad hoc announcement §15 WpHG Final Results Cytori Therapeutics, Inc: Cytori Reports 2006 Fourth Quarter and Year-End Results; Reviews 2006 Progress and Provides 2007 Outlook Ad hoc announcement transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. -------------------------------------------------- Cytori Therapeutics (NASDAQ: CYTX; Frankfurt: XMPA) reports financial results for the quarter and year ended December 31, 2006, reviews 2006 progress, and provides 2007 outlook. Cash, cash equivalents and short term investments were $12.9 million as of December 31, 2006. Subsequent to the end of the year, Cytori raised $20 million from an equity offering and entered into an agreement to raise $6 million as part of a strategic equity agreement with Green Hospital Supply, Inc. Total development revenues for the quarter and year ended December 31, 2006 were $5.2 million and $6.5 million, respectively, compared to $235,000 and $371,000, respectively, for the same period in 2005. The increase in development revenues in the fourth quarter and full year 2006 is due to the recognition of deferred revenue related to the Olympus-Cytori Joint Venture by achieving certain regulatory, preclinical development and Celution™ System development milestones. Product revenues from our non-core biomaterials products for the quarter and year ended December 31, 2006 were $363,000 and $1.5 million, respectively, compared to $858,000 and $5.6 million for the same periods in 2005. Research and development expenses for the quarter and year ended December 31, 2006 were $5.2 million and $22.0 million, respectively, compared to $4.9 million and $15.5 million, respectively, for the same periods in 2005. The increase in R&D for the full year 2006 is attributed to additional preclinical studies, preparations for upcoming clinical trials, increased Celution™ System development expenses to attain regulatory approvals, and internal scale-up for manufacturing of devices and consumables for clinical trials. General and administrative expenses for the quarter and year ended December 31, 2006 were $2.5 million and $12.5 million, respectively, compared to $2.2 million and $10.2 million, respectively, for the same periods in 2005. Net loss for the quarter and year ended December 31, 2006 was $1.9 million, or $(0.10) per common share, and $25.4 million, or $(1.53) per common share. This compares to a net loss of $14.4 million, or $(0.96) per common share and $26.5 million, or $(1.80) per common share, respectively, for the same periods in 2005. Cytori anticipates achieving the following milestones in 2007: • Initiate the APOLLO heart attack safety and feasibility trial • Announce the outcome of the investigator-initiated breast reconstruction safety and feasibility study in Japan; • Initiate a multi-center breast reconstruction efficacy trial in Europe in patients who underwent partial-mastectomy; • Expand the Celution™ System distribution network for reconstructive surgery • Build out internal Celution™ System manufacturing capabilities to meet anticipated product demand in early 2008; • Pursue commercialization partners for the Celution™ System in select therapeutic areas; and • Enter a commercialization agreement for adipose stem cell banking -------------------------------------------------- Information and Explaination of the Issuer to this News: 2006 Review 'In 2006 we made significant strides toward commercializing the Celution™ System in early 2008,' said Christopher J. Calhoun, chief executive officer for Cytori. 'This included the first clinical experience for the Celution™ System as part of a breast reconstruction safety and feasibility study, attaining key regulatory milestones and adding critical design components to tailor the Celution™ System to reconstructive surgery. 'In addition, we laid extensive groundwork to start two cardiovascular disease clinical trials. This included the completion of important preclinical research that helped us design and implement controlled, randomized dose-escalation studies. Our PRECISE chronic heart disease trial began enrollment in January 2007 and our APOLLO acute heart attack trial is expected to receive approval and begin enrolling patients next quarter.' 2007 Outlook 'Our major 2007 initiatives are to prepare for commercialization, execute strategic partnerships and advance our cardiovascular products through clinical development,' added Mr. Calhoun. 'We believe the buildup to our 2008 product launch can significantly increase Cytori’s intrinsic value as we get closer to generating regenerative medicine product revenues.' Conference Call Information The management of Cytori Therapeutics will host a conference call today at 10:00 a.m. Eastern Daylight Time (EDT) or 4:00 p.m. Central European Summer Time (CEST). The conference call will be webcast live and may be accessed under 'Events & Webcasts' in the Investor Relations section of the Company's website at http://www.cytoritx.com. The archived version of the webcast will be available two hours after the call on the company's website and accessible for 14 days. A telephone replay will be available for one week. To access the replay, please call +1 (303) 590-3000 (PIN: 11086131#). Cautionary Statement Regarding Forward-Looking Statements This press release includes forward-looking statements regarding events, trends and prospects of our business, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties, dependence on performance of third parties, and other risks and uncertainties described (under the heading 'Risk Factors') in Cytori Therapeutics' Form 10-K annual report for the year ended December 31, 2006. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made. (c)DGAP 30.03.2007 -------------------------------------------------- Language: English Issuer: Cytori Therapeutics, Inc. 6740 Top Gun Street 92121 San Diego, CA Vereinigte Staaten von Amerika Phone: 001-858 / 736 5485 Fax: 001-858 / 458 0994 E-mail: sbacher@cytoritx.com www: www.cytoritx.com ISIN: US23283K1051 WKN: A0ETV6 Indices: PRIMEALL, TECHALLSHARE Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-Bremen, Stuttgart, München, Düsseldorf End of News DGAP News-Service

 

hatten da manche noch mehr erwartet? Oder was ist der Grund?
Tschau Gretel  

haben noch niemandem geschadet.  

Und das nicht genau auf Wochen-topp geschlossen wird, ist erst recht Freitags normal.

Cytori macht 2007 noch sattes minus. Gemeinsam mit Olympus werden jetzt die Celution-Maschinen produziert, von denen sie ausgehen, sie ab 2008 ordentlich verkaufen zu können. Ab mitte 2008 wird absehbar kräftig verdient und das könnte reichen ohne weitere KEs, denn für verschiedene andere Anwendungen könnten noch Partner aufspringen wollen. Und die müssen jeweils Geld mitbringen. :-)  

©

Es genügt nicht, keine Gedanken zu haben, man muss auch unfähig sein, sie auszudrücken.  

 

Alleine mehrere 100 mio Dollar für Brustanwendung nach Brustkrebs-OP, und das ist ja nur ein Mini-Spektrum!

Cytori could be the first company to launch a stem cell-based medical device, while Osiris hopes to launch the first stem cell drug.
By Aaron Smith, CNNMoney.com staff writer
April 5 2007: 11:43 AM EDT


NEW YORK (CNNMoney.com) -- Two new stem cell treatments could be entering the U.S. market next year.

Two biotechs, Cytori Therapeutics and Osiris Therapeutics, each hope to get their experimental stem cell products approved by the Food and Drug Administration and into the U.S. market by 2008.

Related
Pity the poor drug rep
Glaxo seeks approval for cervical cancer vaccine
Take this pill and shove it!


Video More video


CNN\'s Ali Velshi talks to GlaxoSmithKline CEO Jean Pierre Garnier about its new breast cancer drug. (March 17)
Play video



Both outfits work with stem cells that are derived from adult tissue, not embryos, so they\'re insulated from the controversy surrounding the use of stem cells harvested from human embryos. Other companies, like Geron (up $0.22 to $7.48, Charts) and Advanced Cell Technologies, do use embryos as a source for their stem cells.

Stem cells serve as the body\'s repair system. Theoretically they can divide without limit and morph into different types of cells, according to the National Institutes of Health. Researchers hope to harness these cells for use in therapies that can heal crippling trauma, like brain damage or spinal injury, or to reverse disabling disease like Parkinson\'s or Alzheimer\'s.

Cytori (down $0.02 to $5.62, Charts) is planning to launch its first stem cell medical device in Europe this year, said Eric Daniels, senior director of business development for the company, with a market debut planned for Spain and Italy. The company\'s Celution System uses stem cell technology to rebuild breast tissue in cancer survivors.

After the European launch, Cytori hopes that the Food and Drug Administration will grant its product full approval for a late 2008 entry in the U.S. market, said Daniels.

The Celution System extracts stem cells from liposuction fat, which are then used to grow breast tissue in women who have undergone partial mastectomies to remove cancer, said Daniels.

"It turns out that subcutaneous fat is a very rich source of stem and regenerative cells," he said. The device would be used to inject "a cocktail of therapeutic cells" into the woman\'s body. Daniels speculated that product sales could reach several hundred million dollars a year.

Stephen Brozak, analyst for WBB Securities (which does not own any Cytori shares, but does act as a financial advisor for the company), has high hopes for the Celution System, which he sees as a potential blockbuster.

"This is the billion dollar product," said Brozak, who added that the first FDA-approved stem cell device would "spur an R&D war the likes of which biotechnology has not seen before."

Rats walk but money waits
Osiris (down $0.29 to $18.47, Charts), based in Columbus, Maryland, currently has the only stem cell-based product that\'s been approved by the FDA. OsteoCell, which stimulates bone growth and is already on the U.S. market, is actually considered an implant rather than a drug or device.

But Osiris also has a potential stem cell drug in its pipeline - Prochymal - that CEO Randal Mills wants to launch into the U.S. market, possibly by 2008.

"We want to be the first company to get a stem cell drug approved by the FDA," said Mills. He said that Prochymal, a potential treatment for acute Graft vs. Host Disease (also known as GVHD) and Crohn\'s disease, is in late-stage trials. GVHD is an immune condition affecting cancer survivors with bone marrow transplants, while Crohn\'s causes inflammation of the intestinal tract.

The stem cell arena, which also includes companies like StemCells Inc., (up $0.21 to $2.97, Charts) Aastrom Biosciences (up $0.09 to $1.58, Charts), and Thermogenesis, is tiny. The industry\'s sole product, Osiris\' OsteoCell, had 2006 sales of just $8 million.

But analysts believe the market will swell to immense proportions. Robin Young, analyst for the orthopedics research firm RRY Publications, projects that the stem cell market will grow to $8.5 billion by 2016. Young envisions stem cell therapeutics in the areas of orthopedics, diabetes, anti-inflammatory or autoimmune diseases, nerve repair and heart disease.

WBB Securities analyst Brozak thinks that the most lucrative market for stem cell treatments will be heart disease.

"The Holy Grail that you\'re looking at on the stem cell side are indications that have to deal with heart damage," said Brozak. "One of the most successful stem cell applications could be rebuilding damaged hearts, because heart disease is the number one killer in America and the market for treating it is huge."

Robots grab chunk of prostate cancer surgery biz

Drug stocks  

So wie sich das anhört, könnte mein 3k-Invest ab 08 doch zu einem lukrativen part werden. Ich glaube jedenfalls daran. Bei Rücksetzern sollte nachgeladen werden.